New drug combo for advanced bile duct and gallbladder cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two new drugs, AK130 and AK112, for people with advanced bile duct or gallbladder cancer that has stopped responding to standard chemotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced bile duct or gallbladder cancer that got worse after one prior treatment.
- You are able to get out of bed and care for yourself (ECOG 0 or 1).
- You have at least one tumor that can be measured on a scan and has not been treated with radiation.
- Your major organs (like liver, kidneys, bone marrow) are working well enough.
- You have not had another cancer in the last 3 years (except certain early or skin cancers).
- You do not have cancer that has spread to the brain or fluid buildup in your chest or belly that needs draining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination treatment for biliary tract cancer that is borderline resectable or locally advanced. It combines a chemotherapy infusions directly into the liver (HAIC) with an immunotherapy drug (adebrelimab) and a targeted therapy pill (lenvatinib), aiming to shrink the tumor enough to allow surgery.
This trial tests a new combination of three drugs (anlotinib, nab-paclitaxel, and S-1) for people with advanced bile duct or gallbladder cancer that has progressed after first-line chemotherapy. The goal is to see if this combination can help control the cancer better than standard second-line options.
This trial tests a new immunotherapy drug called AK112 for people with advanced liver cancer that hasn't spread to the brain or key blood vessels. It may be an option if you haven't had immunotherapy before and your liver is still working well.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pembrolizumab, for people with advanced bile duct or gallbladder cancer that has grown after previous treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.